Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1

Interventions

Dexamethasone 87 daratumumab 49 Lenalidomide 49 pomalidomide 33 Bortezomib 32 Cyclophosphamide 31 carfilzomib 25 Calcium Dobesilate 21 talquetamab 19 fludarabine 18 isatuximab 16 iberdomide 16 Magnetic Resonance Spectroscopy 16 Specimen Handling 15 Biopsy 14 selinexor 12 Melphalan 11 belantamab mafodotin 10 dexamethasone acetate 9 dexamethasone 21-phosphate 8 elotuzumab 7 auricularum 7 venetoclax 6 tocilizumab 5 fludarabine phosphate 5 X-Rays 5 Blood Specimen Collection 5 ruxolitinib 4 Methylprednisolone 4 Injections 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Multiple Myeloma × letermovir × Clear all

NCT06920251 2025-12-03

OPTIMUS-EL

Seoul National University Hospital

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡